3.80
1.81%
-0.07
After Hours:
3.78
-0.02
-0.53%
Fate Therapeutics Inc stock is currently priced at $3.80, with a 24-hour trading volume of 2.73M.
It has seen a -1.81% decreased in the last 24 hours and a -44.61% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.93 pivot point. If it approaches the $3.72 support level, significant changes may occur.
Previous Close:
$3.87
Open:
$3.88
24h Volume:
2.73M
Market Cap:
$432.38M
Revenue:
$63.53M
Net Income/Loss:
$-160.93M
P/E Ratio:
-1.7512
EPS:
-2.17
Net Cash Flow:
$-138.42M
1W Performance:
-20.67%
1M Performance:
-44.61%
6M Performance:
+117.14%
1Y Performance:
-34.71%
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858-875-1800
Address
3535 General Atomics Court, Suite 200, San Diego, CA
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-06-23 | Downgrade | Stifel | Buy → Hold |
Jan-06-23 | Downgrade | Truist | Buy → Hold |
Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-15-22 | Initiated | Goldman | Sell |
Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Oct-10-22 | Initiated | Canaccord Genuity | Buy |
Aug-18-22 | Resumed | Wells Fargo | Overweight |
Jul-28-22 | Initiated | Needham | Hold |
Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jun-03-22 | Initiated | Robert W. Baird | Neutral |
Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
Dec-07-21 | Initiated | Cowen | Outperform |
Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
Apr-26-21 | Resumed | Jefferies | Buy |
Feb-26-21 | Initiated | BofA Securities | Buy |
Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
May-13-20 | Initiated | H.C. Wainwright | Buy |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-30-19 | Reiterated | Mizuho | Buy |
Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Nov-12-19 | Initiated | SunTrust | Buy |
Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
Oct-01-19 | Initiated | Stifel | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
Jul-12-19 | Initiated | Oppenheimer | Outperform |
Jun-13-19 | Initiated | Mizuho | Buy |
Jun-07-19 | Initiated | ROTH Capital | Neutral |
May-31-19 | Initiated | Guggenheim | Buy |
May-24-19 | Resumed | Citigroup | Buy |
Mar-28-19 | Initiated | SVB Leerink | Outperform |
Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
Nov-05-18 | Initiated | Jefferies | Buy |
Aug-01-18 | Initiated | Citigroup | Buy |
Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
GlobeNewswire Inc.
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks Investment Research
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Zacks Investment Research
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Zacks Investment Research
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Zacks Investment Research
What's in Store for Biogen (BIIB) This Earnings Season?
Zacks Investment Research
Fate Therapeutics Inc Stock (FATE) Financials Data
Fate Therapeutics Inc (FATE) Revenue 2024
FATE reported a revenue (TTM) of $63.53 million for the quarter ending December 31, 2023, a -34.03% decline year-over-year.
Fate Therapeutics Inc (FATE) Net Income 2024
FATE net income (TTM) was -$160.93 million for the quarter ending December 31, 2023, a +42.88% increase year-over-year.
Fate Therapeutics Inc (FATE) Cash Flow 2024
FATE recorded a free cash flow (TTM) of -$138.42 million for the quarter ending December 31, 2023, a +51.22% increase year-over-year.
Fate Therapeutics Inc (FATE) Earnings per Share 2024
FATE earnings per share (TTM) was -$1.64 for the quarter ending December 31, 2023, a +43.64% growth year-over-year.
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells; and a collaboration agreement with ONO Pharmaceutical Co., Ltd. for the development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):